Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals ($SPRY), sold company shares on the open market three times over the past year, for a total of about $635,000. His most recent SPRY insider sale was on July 1, 2025. These transactions rank 5,969th among 11,678 individual insiders, below the average sale value of $8.6 million across 6.4 transactions. Karas made no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | A | Stock option (right to buy) | 240000 | $0.00 | 240,000.0000 | 98,807,600 | 9999.99% | 0.24% |
| July 1, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | S | Common Stock | 15000 | $16.99 | 10,315.0000 | 102,390,828 | 59.25% | 0.01% |
| July 1, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Stock Option (Right to Buy) | 15000 | $0.00 | 544,588.0000 | 102,390,828 | 2.68% | 0.01% |
| July 1, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Common Stock | 15000 | $1.50 | 25,315.0000 | 102,390,828 | 145.42% | 0.01% |
| June 18, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | S | Common Stock | 15000 | $16.00 | 7,696.0000 | 102,390,828 | 66.09% | 0.01% |
| June 18, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Stock Option (Right to Buy) | 15000 | $0.00 | 559,588.0000 | 102,390,828 | 2.61% | 0.01% |
| June 18, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Common Stock | 15000 | $1.50 | 22,696.0000 | 102,390,828 | 194.91% | 0.01% |
| March 20, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | S | Common Stock | 10000 | $14.00 | 7,696.0000 | 102,390,828 | 56.51% | 0.01% |
| March 20, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 574,588.0000 | 102,390,828 | 1.71% | 0.01% |
| March 20, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Common Stock | 10000 | $1.50 | 17,696.0000 | 102,390,828 | 129.94% | 0.01% |
| Jan. 2, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | A | Stock option (right to buy) | 152300 | $0.00 | 152,300.0000 | 102,390,828 | 9999.99% | 0.15% |
| Dec. 2, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | S | Common Stock | 3717 | $14.11 | 5,693.0000 | 97,032,331 | 39.50% | 0.00% |
| Dec. 4, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Common Stock | 6283 | $1.50 | 11,976.0000 | 97,032,331 | 110.36% | 0.01% |
| Dec. 4, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | S | Common Stock | 6283 | $14.00 | 5,693.0000 | 97,032,331 | 52.46% | 0.01% |
| Dec. 2, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Stock Option (Right to Buy) | 3717 | $0.00 | 590,871.0000 | 97,032,331 | 0.63% | 0.00% |
| Dec. 4, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Stock Option (Right to Buy) | 6283 | $0.00 | 584,588.0000 | 97,032,331 | 1.06% | 0.01% |
| Dec. 2, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Common Stock | 3717 | $1.50 | 9,410.0000 | 97,032,331 | 65.29% | 0.00% |
| Sept. 18, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | S | Common Stock | 10000 | $14.00 | 5,693.0000 | 95,215,322 | 63.72% | 0.01% |
| Sept. 18, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 594,588.0000 | 95,215,322 | 1.65% | 0.01% |
| Sept. 18, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Common Stock | 10000 | $1.50 | 15,693.0000 | 95,215,322 | 175.65% | 0.01% |
| Aug. 19, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | S | Common Stock | 10000 | $14.00 | 5,693.0000 | 95,215,322 | 63.72% | 0.01% |
| Aug. 19, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 604,588.0000 | 95,215,322 | 1.63% | 0.01% |
| Aug. 19, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | M | Common Stock | 10000 | $1.50 | 15,693.0000 | 95,215,322 | 175.65% | 0.01% |
| Jan. 2, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | A | Stock option (right to buy) | 200000 | $0.00 | 200,000.0000 | 95,215,322 | 9999.99% | 0.21% |
| Jan. 3, 2023 | ARS Pharmaceuticals, Inc. | $SPRY | Karas Eric | Chief Commercial Officer | A | Stock option (right to buy) | 50000 | $0.00 | 50,000.0000 | 0 | 9999.99% | 0.00% |